Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Different Sides of Depression in the Elderly: An In-depth View on the Role of Aβ Peptides

Author(s): Giovanni Pagni*, Claudia Tagliarini, Manuel Glauco Carbone, Bruno Pietro Imbimbo, Donatella Marazziti and Nunzio Pomara

Volume 29, Issue 36, 2022

Published on: 10 January, 2022

Page: [5731 - 5757] Pages: 27

DOI: 10.2174/0929867328666210921164816

Price: $65

Abstract

Background: Late-onset depression (LOD) is the most common neuropsychiatric disorder associated with Alzheimer's disease (AD), often associated with structural and functional brain changes, neuropsychological impairments and negative family history for affective disorders. LOD could be a risk factor or a prodromal phase of AD; this has led to the investigation of the link between depression and amyloid-β (Aβ) peptides by measuring Aβ levels in plasma, cerebrospinal fluid (CSF) and brains of elderly depressed subjects.

Objective: This study aims to clarify the complex relationship between depression, Aβ peptides and AD.

Methods: We evaluated all articles published up to 2019 in PubMed in which Aβ was measured in serum (or plasma), CSF or brain in elderly with Major Depressive Disorder or depressive symptoms evaluated with standard scales.

Results: Low plasma Aβ42 levels are strongly associated with depression severity. Plasma Aβ40 levels are higher in younger depressed, drug-resistant and those with more severe symptoms. CSF Aβ42 levels are lower in depressed than controls. PET-detected global and region-specific increases in Aβ deposition are sometimes associated with LOD, cognitive impairment, anxiety but not with Cardiovascular Diseases (CVDs)/CVD risk factors. Elderly depressed with CVDs/CVD risk factors have more frequently high plasma Aβ40 levels and drug-resistance; those without

Conclusion: Two specific Aβ profiles emerge in the depressed elderly. One is associated with Aβ42 reductions in plasma and CSF, possibly reflecting increased brain amyloid deposition and prodromal AD. The other one is characterized by high plasma Aβ40 levels, cerebrovascular disease and is clinically associated with increased AD risk.

Keywords: Late-onset depression, Aβ-peptides, Alzheimer's disease, amyloid PET, CSF, cardiovascular risk factors.

« Previous Next »
[1]
McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E.M. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Dis-ease. Neurology, 1984, 34(7), 939-944.
[http://dx.doi.org/10.1212/WNL.34.7.939] [PMID: 6610841]
[2]
Cummings, J.L.; Victoroff, J.I. Noncognitive neuropsychiatric syndromes in Alzheimer’s disease. Neuropsychiatry Neuropsychol. Behav. Neurol., 1990, 3, 140-158.
[3]
García-Alberca, J.M.; Pablo Lara, J.; González-Barón, S.; Barbancho, M.A.; Porta, D.; Berthier, M. Prevalence and comorbidity of neu-ropsychiatric symptoms in Alzheimer’s disease. Actas Esp. Psiquiatr., 2008, 36(5), 265-270.
[PMID: 18597200]
[4]
Bateman, R.J.; Aisen, P.S.; De Strooper, B. Autosomal‐dominant Alzheimer’s disease: a review and proposal for the prevention of Alz-heimer’s disease. Alzheimers Res. Ther., 2010, 3, 1.
[5]
Verghese, P.B.; Castellano, J.M.; Holtzman, D.M. Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol., 2011, 10(3), 241-252.
[http://dx.doi.org/10.1016/S1474-4422(10)70325-2] [PMID: 21349439]
[6]
Karch, C.M.; Goate, A.M. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry, 2015, 77(1), 43-51.
[http://dx.doi.org/10.1016/j.biopsych.2014.05.006] [PMID: 24951455]
[7]
Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol., 1991, 82(4), 239-259.
[http://dx.doi.org/10.1007/BF00308809] [PMID: 1759558]
[8]
Mirra, S.S.; Heyman, A.; McKeel, D.; Sumi, S.M.; Crain, B.J.; Brownlee, L.M.; Vogel, F.S.; Hughes, J.P.; van Belle, G.; Berg, L. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology, 1991, 41(4), 479-486.
[http://dx.doi.org/10.1212/WNL.41.4.479] [PMID: 2011243]
[9]
Thal, D.R.; Rüb, U.; Orantes, M.; Braak, H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology, 2002, 58(12), 1791-1800.
[http://dx.doi.org/10.1212/WNL.58.12.1791] [PMID: 12084879]
[10]
Bowen, D.M.; Smith, C.B.; White, P.; Davison, A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain, 1976, 99(3), 459-496.
[http://dx.doi.org/10.1093/brain/99.3.459] [PMID: 11871]
[11]
Belleville, S.; Peretz, I.; Malenfant, D. Examination of the working memory components in normal aging and in dementia of the Alz-heimer type. Neuropsychologia, 1996, 34(3), 195-207.
[http://dx.doi.org/10.1016/0028-3932(95)00097-6] [PMID: 8868277]
[12]
Bartus, R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation follow-ing the cholinergic hypothesis. Exp. Neurol., 2000, 163(2), 495-529.
[http://dx.doi.org/10.1006/exnr.2000.7397] [PMID: 10833325]
[13]
Spires-Jones, T.L.; Hyman, B.T. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron, 2014, 82(4), 756-771.
[http://dx.doi.org/10.1016/j.neuron.2014.05.004] [PMID: 24853936]
[14]
Lanctôt, K.L.; Herrmann, N.; Yau, K.K.; Khan, L.R.; Liu, B.A. LouLou, M.M.; Einarson, T.R. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ, 2003, 169(6), 557-564.
[PMID: 12975222]
[15]
Przybyłowska, M.; Kowalski, S.; Dzierzbicka, K.; Inkielewicz-Stepniak, I. Therapeutic potential of multifunctional tacrine analogues. Curr. Neuropharmacol., 2019, 17(5), 472-490.
[http://dx.doi.org/10.2174/1570159X16666180412091908] [PMID: 29651948]
[16]
Gomez-Isla, T.; Spires-Jones, T.L.; de Calignon, A.; Hyman, B. Neuropathology of Alzheimer’s disease. Clin. Neurol., 2008, 89, 233-243.
[17]
Turner, P.R.; O’Connor, K.; Tate, W.P.; Abraham, W.C. Roles of amyloid precursor protein and its fragments in regulating neural activi-ty, plasticity and memory. Prog. Neurobiol., 2003, 70(1), 1-32.
[http://dx.doi.org/10.1016/S0301-0082(03)00089-3] [PMID: 12927332]
[18]
Sisodia, S.S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. USA, 1992, 89(13), 6075-6079.
[http://dx.doi.org/10.1073/pnas.89.13.6075] [PMID: 1631093]
[19]
Hampel, H.; Shen, Y. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer’s disease. Scand. J. Clin. Lab. Invest., 2009, 69(1), 8-12.
[http://dx.doi.org/10.1080/00365510701864610] [PMID: 18609117]
[20]
Thinakaran, G.; Borchelt, D.R.; Lee, M.K.; Slunt, H.H.; Spitzer, L.; Kim, G.; Ratovitsky, T.; Davenport, F.; Nordstedt, C.; Seeger, M.; Hardy, J.; Levey, A.I.; Gandy, S.E.; Jenkins, N.A.; Copeland, N.G.; Price, D.L.; Sisodia, S.S. Endoproteolysis of presenilin 1 and ac-cumulation of processed derivatives in vivo. Neuron, 1996, 17(1), 181-190.
[http://dx.doi.org/10.1016/S0896-6273(00)80291-3] [PMID: 8755489]
[21]
Vassar, R. BACE1: the beta-secretase enzyme in Alzheimer’s disease. J. Mol. Neurosci., 2004, 23(1-2), 105-114.
[http://dx.doi.org/10.1385/JMN:23:1-2:105] [PMID: 15126696]
[22]
Pomara, N.; Murali Doraiswamy, P. Does increased platelet release of Abeta peptide contribute to brain abnormalities in individuals with depression? Med. Hypotheses, 2003, 60(5), 640-643.
[http://dx.doi.org/10.1016/S0306-9877(02)00380-8] [PMID: 12710895]
[23]
Kuo, Y.M.; Kokjohn, T.A.; Kalback, W.; Luehrs, D.; Galasko, D.R.; Chevallier, N.; Koo, E.H.; Emmerling, M.R.; Roher, A.E. Amy-loid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem. Biophys. Res. Commun., 2000, 268(3), 750-756.
[http://dx.doi.org/10.1006/bbrc.2000.2222] [PMID: 10679277]
[24]
Mawuenyega, K.G.; Sigurdson, W.; Ovod, V.; Munsell, L.; Kasten, T.; Morris, J.C.; Yarasheski, K.E.; Bateman, R.J. Decreased clear-ance of CNS beta-amyloid in Alzheimer’s disease. Science, 2010, 330(6012), 1774.
[http://dx.doi.org/10.1126/science.1197623] [PMID: 21148344]
[25]
Chen, D.W.; Wang, J.; Zhang, L.L.; Wang, Y.J.; Gao, C.Y. Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with In-somnia. J. Alzheimers Dis., 2018, 61(2), 645-651.
[http://dx.doi.org/10.3233/JAD-170032] [PMID: 29278891]
[26]
Irwin, M.R.; Vitiello, M.V. Implications of sleep disturbance and inflammation for Alzheimer’s disease dementia. Lancet Neurol., 2019, 18(3), 296-306.
[http://dx.doi.org/10.1016/S1474-4422(18)30450-2] [PMID: 30661858]
[27]
Pomara, N.; Greenberg, W.M.; Branford, M.D.; Doraiswamy, P.M. Therapeutic implications of HPA axis abnormalities in Alzheimer’s disease: review and update. Psychopharmacol. Bull., 2003, 37(2), 120-134.
[PMID: 14674372]
[28]
Morgese, M.G.; Tucci, P.; Colaianna, M.; Zotti, M.; Cuomo, V.; Schiavone, S.; Trabace, L. Modulatory activity of soluble beta amyloid on HPA axis function in rats. Curr. Pharm. Des., 2014, 20(15), 2539-2546.
[http://dx.doi.org/10.2174/13816128113199990500] [PMID: 23859549]
[29]
Bitan, G.; Vollers, S.S.; Teplow, D.B. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J. Biol. Chem., 2003, 278(37), 34882-34889.
[http://dx.doi.org/10.1074/jbc.M300825200] [PMID: 12840029]
[30]
Bitan, G.; Kirkitadze, M.D.; Lomakin, A.; Vollers, S.S.; Benedek, G.B.; Teplow, D.B. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA, 2003, 100(1), 330-335.
[http://dx.doi.org/10.1073/pnas.222681699] [PMID: 12506200]
[31]
Gong, Y.; Chang, L.; Viola, K.L.; Lacor, P.N.; Lambert, M.P.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA, 2003, 100(18), 10417-10422.
[http://dx.doi.org/10.1073/pnas.1834302100] [PMID: 12925731]
[32]
Ahmed, M.; Davis, J.; Aucoin, D.; Sato, T.; Ahuja, S.; Aimoto, S.; Elliott, J.I.; Van Nostrand, W.E.; Smith, S.O. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat. Struct. Mol. Biol., 2010, 17(5), 561-567.
[http://dx.doi.org/10.1038/nsmb.1799] [PMID: 20383142]
[33]
Fagan, A.M.; Mintun, M.A.; Mach, R.H.; Lee, S.Y.; Dence, C.S.; Shah, A.R.; LaRossa, G.N.; Spinner, M.L.; Klunk, W.E.; Mathis, C.A.; DeKosky, S.T.; Morris, J.C.; Holtzman, D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol., 2006, 59(3), 512-519.
[http://dx.doi.org/10.1002/ana.20730] [PMID: 16372280]
[34]
Strozyk, D.; Blennow, K.; White, L.R.; Launer, L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology, 2003, 60(4), 652-656.
[http://dx.doi.org/10.1212/01.WNL.0000046581.81650.D0] [PMID: 12601108]
[35]
Buchhave, P.; Minthon, L.; Zetterberg, H.; Wallin, A.K.; Blennow, K.; Hansson, O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry, 2012, 69(1), 98-106.
[http://dx.doi.org/10.1001/archgenpsychiatry.2011.155] [PMID: 22213792]
[36]
Roher, A.E.; Esh, C.L.; Kokjohn, T.A.; Castaño, E.M.; Van Vickle, G.D.; Kalback, W.M.; Patton, R.L.; Luehrs, D.C.; Daugs, I.D.; Kuo, Y.M.; Emmerling, M.R.; Soares, H.; Quinn, J.F.; Kaye, J.; Connor, D.J.; Silverberg, N.B.; Adler, C.H.; Seward, J.D.; Beach, T.G.; Sabbagh, M.N. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement., 2009, 5(1), 18-29.
[http://dx.doi.org/10.1016/j.jalz.2008.10.004] [PMID: 19118806]
[37]
Kokjohn, T.A.; Van Vickle, G.D.; Maarouf, C.L.; Kalback, W.M.; Hunter, J.M.; Daugs, I.D.; Luehrs, D.C.; Lopez, J.; Brune, D.; Sue, L.I.; Beach, T.G.; Castaño, E.M.; Roher, A.E. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atheroscle-rotic lesions and platelets. Biochim. Biophys. Acta, 2011, 1812(11), 1508-1514.
[http://dx.doi.org/10.1016/j.bbadis.2011.07.004] [PMID: 21784149]
[38]
Weyerer, S.; Eifflaender-Gorfer, S.; Köhler, L.; Jessen, F.; Maier, W.; Fuchs, A.; Pentzek, M.; Kaduszkiewicz, H.; Bachmann, C.; An-germeyer, M.C.; Luppa, M.; Wiese, B.; Mösch, E.; Bickel, H. Prevalence and risk factors for depression in non-demented primary care attenders aged 75 years and older. J. Affect. Disord., 2008, 111(2-3), 153-163.
[http://dx.doi.org/10.1016/j.jad.2008.02.008] [PMID: 18372049]
[39]
Alibasic, E.; Ramic, E.; Bajraktarevic, A.; Karic, E.; Batic-Mujanovic, O.; Ramic, I.; Alibasic, E. Geriatric depression in family medicine. Mater. Sociomed., 2018, 30(1), 26-28.
[http://dx.doi.org/10.5455/msm.2018.30.26-28] [PMID: 30429685]
[40]
Baldwin, R.C.; Tomenson, B. Depression in later life. A comparison of symptoms and risk factors in early and late onset cases. Br. J. Psychiatry, 1995, 167(5), 649-652.
[http://dx.doi.org/10.1192/bjp.167.5.649] [PMID: 8564322]
[41]
Brodaty, H.; Luscombe, G.; Parker, G.; Wilhelm, K.; Hickie, I.; Austin, M.P.; Mitchell, P. Early and late onset depression in old age: different aetiologies, same phenomenology. J. Affect. Disord., 2001, 66(2-3), 225-236.
[http://dx.doi.org/10.1016/S0165-0327(00)00317-7] [PMID: 11578676]
[42]
Krishnan, K.R.; Hays, J.C.; Tupler, L.A.; George, L.K.; Blazer, D.G. Clinical and phenomenological comparisons of late-onset and ear-ly-onset depression. Am. J. Psychiatry, 1995, 152(5), 785-788.
[http://dx.doi.org/10.1176/ajp.152.5.785] [PMID: 7726320]
[43]
Van den Berg, M.D.; Oldehinkel, A.J.; Bouhuys, A.L.; Brilman, E.I.; Beekman, A.T.; Ormel, J. Depression in later life: three etiologi-cally different subgroups. J. Affect. Disord., 2001, 65(1), 19-26.
[http://dx.doi.org/10.1016/S0165-0327(00)00263-9] [PMID: 11426505]
[44]
Alexopoulos, G.S.; Kiosses, D.N.; Klimstra, S.; Kalayam, B.; Bruce, M.L. Clinical presentation of the “depression-executive dysfunc-tion syndrome” of late life. Am. J. Geriatr. Psychiatry, 2002, 10(1), 98-106.
[PMID: 11790640]
[45]
Hickie, I.; Naismith, S.; Ward, P.B.; Turner, K.; Scott, E.; Mitchell, P.; Wilhelm, K.; Parker, G. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. Br. J. Psychiatry, 2005, 186, 197-202.
[http://dx.doi.org/10.1192/bjp.186.3.197] [PMID: 15738499]
[46]
Schweitzer, I.; Tuckwell, V.; Ames, D.; O’Brien, J. Structural neuroimaging studies in late-life depression: a review. World J. Biol. Psychiatry, 2001, 2(2), 83-88.
[http://dx.doi.org/10.3109/15622970109027497] [PMID: 12587189]
[47]
Hickie, I.; Scott, E.; Mitchell, P.; Wilhelm, K.; Austin, M.P.; Bennett, B. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol. Psychiatry, 1995, 37(3), 151-160.
[http://dx.doi.org/10.1016/0006-3223(94)00174-2] [PMID: 7727623]
[48]
Hickie, I.; Scott, E.; Wilhelm, K.; Brodaty, H. Subcortical hyperintensities on magnetic resonance imaging in patients with severe depres-sion--a longitudinal evaluation. Biol. Psychiatry, 1997, 42(5), 367-374.
[http://dx.doi.org/10.1016/S0006-3223(96)00363-0] [PMID: 9276077]
[49]
Naismith, S.L.; Hickie, I.B.; Turner, K.; Little, C.L.; Winter, V.; Ward, P.B.; Wilhelm, K.; Mitchell, P.; Parker, G. Neuropsychological performance in patients with depression is associated with clinical, etiological and genetic risk factors. J. Clin. Exp. Neuropsychol., 2003, 25(6), 866-877.
[http://dx.doi.org/10.1076/jcen.25.6.866.16472] [PMID: 13680463]
[50]
Lee, H.B.; Lyketsos, C.G. Depression in Alzheimer’s disease: heterogeneity and related issues. Biol. Psychiatry, 2003, 54(3), 353-362.
[http://dx.doi.org/10.1016/S0006-3223(03)00543-2] [PMID: 12893110]
[51]
Craig, D.; Mirakhur, A.; Hart, D.J.; McIlroy, S.P.; Passmore, A.P. A cross-sectional study of neuropsychiatric symptoms in 435 pa-tients with Alzheimer’s disease. Am. J. Geriatr. Psychiatry, 2005, 13(6), 460-468.
[http://dx.doi.org/10.1097/00019442-200506000-00004] [PMID: 15956265]
[52]
Butt, Z.A.; Strauss, M.E. Relationship of family and personal history to the occurrence of depression in persons with Alzheimer’s dis-ease. Am. J. Geriatr. Psychiatry, 2001, 9(3), 249-254.
[http://dx.doi.org/10.1097/00019442-200108000-00008] [PMID: 11481132]
[53]
Lyketsos, C.G.; Olin, J. Depression in Alzheimer’s disease: overview and treatment. Biol. Psychiatry, 2002, 52(3), 243-252.
[http://dx.doi.org/10.1016/S0006-3223(02)01348-3] [PMID: 12182930]
[54]
Tsuno, N.; Homma, A. What is the association between depression and Alzheimer’s disease? Expert Rev. Neurother., 2009, 9(11), 1667-1676.
[http://dx.doi.org/10.1586/ern.09.106] [PMID: 19903025]
[55]
Albert, M.S.; DeKosky, S.T.; Dickson, D.; Dubois, B.; Feldman, H.H.; Fox, N.C.; Gamst, A.; Holtzman, D.M.; Jagust, W.J.; Petersen, R.C.; Snyder, P.J.; Carrillo, M.C.; Thies, B.; Phelps, C.H. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: rec-ommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s dis-ease. Alzheimers Dement., 2011, 7(3), 270-279.
[http://dx.doi.org/10.1016/j.jalz.2011.03.008] [PMID: 21514249]
[56]
Byers, A.L.; Yaffe, K. Depression and risk of developing dementia. Nat. Rev. Neurol., 2011, 7(6), 323-331.
[http://dx.doi.org/10.1038/nrneurol.2011.60] [PMID: 21537355]
[57]
Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R., Jr; Kaye, J.; Montine, T.J.; Park, D.C.; Reiman, E.M.; Rowe, C.C.; Siemers, E.; Stern, Y.; Yaffe, K.; Carrillo, M.C.; Thies, B.; Morrison-Bogorad, M.; Wagster, M.V.; Phelps, C.H. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Ag-ing-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement., 2011, 7(3), 280-292.
[http://dx.doi.org/10.1016/j.jalz.2011.03.003] [PMID: 21514248]
[58]
Wells, C.E. Pseudodementia. Am. J. Psychiatry, 1979, 136(7), 895-900.
[http://dx.doi.org/10.1176/ajp.136.7.895] [PMID: 453349]
[59]
Kumar, R.; Parslow, R.A.; Jorm, A.F.; Rosenman, S.J.; Maller, J.; Meslin, C.; Anstey, K.J.; Christensen, H.; Sachdev, P.S. Clinical and neuroimaging correlates of mild cognitive impairment in a middle-aged community sample: the personality and total health through life 60+ study. Dement. Geriatr. Cogn. Disord., 2006, 21(1), 44-50.
[http://dx.doi.org/10.1159/000089251] [PMID: 16254430]
[60]
Ownby, R.L.; Crocco, E.; Acevedo, A.; John, V.; Loewenstein, D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch. Gen. Psychiatry, 2006, 63(5), 530-538.
[http://dx.doi.org/10.1001/archpsyc.63.5.530] [PMID: 16651510]
[61]
Paterniti, S.; Verdier-Taillefer, M.H.; Dufouil, C.; Alpérovitch, A. Depressive symptoms and cognitive decline in elderly people. Longi-tudinal study. Br. J. Psychiatry, 2002, 181, 406-410.
[http://dx.doi.org/10.1192/bjp.181.5.406] [PMID: 12411266]
[62]
Lopez, O.L.; Becker, J.T.; Sweet, R.A.; Klunk, W.; Kaufer, D.I.; Saxton, J.; Habeych, M.; DeKosky, S.T. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J. Neuropsychiatry Clin. Neurosci., 2003, 15(3), 346-353.
[http://dx.doi.org/10.1176/jnp.15.3.346] [PMID: 12928511]
[63]
Wilson, R.S.; Barnes, L.L.; Mendes de Leon, C.F.; Aggarwal, N.T.; Schneider, J.S.; Bach, J.; Pilat, J.; Beckett, L.A.; Arnold, S.E.; Ev-ans, D.A.; Bennett, D.A. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology, 2002, 59(3), 364-370.
[http://dx.doi.org/10.1212/WNL.59.3.364] [PMID: 12177369]
[64]
Barnes, D.E.; Yaffe, K.; Byers, A.L.; McCormick, M.; Schaefer, C.; Whitmer, R.A. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch. Gen. Psychiatry, 2012, 69(5), 493-498.
[http://dx.doi.org/10.1001/archgenpsychiatry.2011.1481] [PMID: 22566581]
[65]
Lee, G.J.; Lu, P.H.; Hua, X.; Lee, S.; Wu, S.; Nguyen, K.; Teng, E.; Leow, A.D.; Jack, C.R., Jr; Toga, A.W.; Weiner, M.W.; Bartzokis, G.; Thompson, P.M. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer’s disease-related regions. Biol. Psychiatry, 2012, 71(9), 814-821.
[http://dx.doi.org/10.1016/j.biopsych.2011.12.024] [PMID: 22322105]
[66]
Ganguli, M.; Du, Y.; Dodge, H.H.; Ratcliff, G.G.; Chang, C.C. Depressive symptoms and cognitive decline in late life: a prospective epidemiological study. Arch. Gen. Psychiatry, 2006, 63(2), 153-160.
[http://dx.doi.org/10.1001/archpsyc.63.2.153] [PMID: 16461857]
[67]
Heun, R.; Kockler, M.; Ptok, U. Depression in Alzheimer’s disease: is there a temporal relationship between the onset of depression and the onset of dementia? Eur. Psychiatry, 2002, 17(5), 254-258.
[http://dx.doi.org/10.1016/S0924-9338(02)00678-8] [PMID: 12381494]
[68]
Weisenbach, S.L.; Boore, L.A.; Kales, H.C. Depression and cognitive impairment in older adults. Curr. Psychiatry Rep., 2012, 14(4), 280-288.
[http://dx.doi.org/10.1007/s11920-012-0278-7] [PMID: 22622478]
[69]
Wright, S.L.; Persad, C. Distinguishing between depression and dementia in older persons: neuropsychological and neuropathological correlates. J. Geriatr. Psychiatry Neurol., 2007, 20(4), 189-198.
[http://dx.doi.org/10.1177/0891988707308801] [PMID: 18004006]
[70]
Barnes, D.E.; Alexopoulos, G.S.; Lopez, O.L.; Williamson, J.D.; Yaffe, K. Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch. Gen. Psychiatry, 2006, 63(3), 273-279.
[http://dx.doi.org/10.1001/archpsyc.63.3.273] [PMID: 16520432]
[71]
Jorm, A.F. History of depression as a risk factor for dementia: an updated review. Aust. N. Z. J. Psychiatry, 2001, 35(6), 776-781.
[http://dx.doi.org/10.1046/j.1440-1614.2001.00967.x] [PMID: 11990888]
[72]
Yaffe, K.; Blackwell, T.; Gore, R.; Sands, L.; Reus, V.; Browner, W.S. Depressive symptoms and cognitive decline in nondemented elderly women: a prospective study. Arch. Gen. Psychiatry, 1999, 56(5), 425-430.
[http://dx.doi.org/10.1001/archpsyc.56.5.425] [PMID: 10232297]
[73]
Dotson, V.M.; Beydoun, M.A.; Zonderman, A.B. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology, 2010, 75(1), 27-34.
[http://dx.doi.org/10.1212/WNL.0b013e3181e62124] [PMID: 20603482]
[74]
Saczynski, J.S.; Beiser, A.; Seshadri, S.; Auerbach, S.; Wolf, P.A.; Au, R. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology, 2010, 75(1), 35-41.
[http://dx.doi.org/10.1212/WNL.0b013e3181e62138] [PMID: 20603483]
[75]
Piccinni, A.; Origlia, N.; Veltri, A.; Vizzaccaro, C.; Marazziti, D.; Vanelli, F.; Moroni, I.; Domenici, L.; Dell’Osso, L. Neurodegenera-tion, β-amyloid and mood disorders: state of the art and future perspectives. Int. J. Geriatr. Psychiatry, 2013, 28(7), 661-671.
[http://dx.doi.org/10.1002/gps.3879] [PMID: 22996674]
[76]
Luppa, M.; Luck, T.; Ritschel, F.; Angermeyer, M.C.; Villringer, A.; Riedel-Heller, S.G. Depression and incident dementia. An 8-year population-based prospective study. PLoS One, 2013, 8(3)e59246
[http://dx.doi.org/10.1371/journal.pone.0059246] [PMID: 23527147]
[77]
Neubauer, A.B.; Wahl, H.W.; Bickel, H. Depressive symptoms as predictor of dementia versus/italic> continuous cognitive decline: a 3-year prospective study.Eur. J. Ageing2012101374810.1007/ s10433-012-0246-428804281
[78]
Wilson, R.S.; Leurgans, S.E.; Boyle, P.A.; Schneider, J.A.; Bennett, D.A. Neurodegenerative basis of age-related cognitive decline. Neurology, 2010, 75(12), 1070-1078.
[http://dx.doi.org/10.1212/WNL.0b013e3181f39adc] [PMID: 20844243]
[79]
Kimura, M.; Curzi, M.L.; Romanowsi, C.P. REM sleep alteration and depression. Arch. Ital. Biol., 2014, 152(2-3), 111-117.
[PMID: 25828683]
[80]
Antonijevic, I. HPA axis and sleep: identifying subtypes of major depression. Stress, 2008, 11(1), 15-27.
[http://dx.doi.org/10.1080/10253890701378967] [PMID: 17853067]
[81]
O’Keane, V.; Frodl, T.; Dinan, T.G. A review of Atypical depression in relation to the course of depression and changes in HPA axis organization. Psychoneuroendocrinology, 2012, 37(10), 1589-1599.
[http://dx.doi.org/10.1016/j.psyneuen.2012.03.009] [PMID: 22497986]
[82]
Lopresti, A.L.; Hood, S.D.; Drummond, P.D. A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise. J. Affect. Disord., 2013, 148(1), 12-27.
[http://dx.doi.org/10.1016/j.jad.2013.01.014] [PMID: 23415826]
[83]
Maetzler, W.; Langkamp, M.; Lerche, S.; Godau, J.; Brockmann, K.; Gaenslen, A.; Huber, H.; Wurster, I.; Niebler, R.; Eschweiler, G.W.; Berg, D. Lowered serum amyloid-β1-42 autoantibodies in individuals with lifetime depression. J. Alzheimers Dis., 2012, 32(1), 95-100.
[http://dx.doi.org/10.3233/JAD-2012-120625] [PMID: 22766733]
[84]
Pomara, N.; Doraiswamy, P.M.; Willoughby, L.M.; Roth, A.E.; Mulsant, B.H.; Sidtis, J.J.; Mehta, P.D.; Reynolds, C.F., III; Pollock, B.G. Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem. Res., 2006, 31(3), 341-349.
[http://dx.doi.org/10.1007/s11064-005-9029-z] [PMID: 16583267]
[85]
Qiu, W.Q.; Sun, X.; Selkoe, D.J.; Mwamburi, D.M.; Huang, T.; Bhadela, R.; Bergethon, P.; Scott, T.M.; Summergrad, P.; Wang, L.; Rosenberg, I.; Folstein, M. Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the home-bound elderly. Int. J. Geriatr. Psychiatry, 2007, 22(6), 536-542.
[http://dx.doi.org/10.1002/gps.1710] [PMID: 17096467]
[86]
Sun, X.; Mwamburi, D.M.; Bungay, K.; Prasad, J.; Yee, J.; Lin, Y.M.; Liu, T.C.; Summergrad, P.; Folstein, M.; Qiu, W.Q. Depression, antidepressants, and plasma amyloid beta (Beta) peptides in those elderly who do not have cardiovascular disease. Biol. Psychiatry, 2007, 62(12), 1413-1417.
[http://dx.doi.org/10.1016/j.biopsych.2007.01.003] [PMID: 17544381]
[87]
Kita, Y.; Baba, H.; Maeshima, H.; Nakano, Y.; Suzuki, T.; Arai, H. Serum amyloid beta protein in young and elderly depression: a pilot study. Psychogeriatrics, 2009, 9(4), 180-185.
[http://dx.doi.org/10.1111/j.1479-8301.2009.00293.x] [PMID: 20377819]
[88]
Qiu, W.Q.; Sun, X.; Mwamburi, D.M.; Haker, J.; Lisle, D.; Rizal, A.; Lin, Y.M.; Qiao, L.; Summergrad, P.; Folstein, M.; Rosenberg, I. Plasma Amyloid-β Peptides and Homocysteine in Depression in the Homebound Elderly. N. Am. J. Med. Sci. (Boston), 2010, 3(2), 61-67.
[http://dx.doi.org/10.7156/v3i2p061] [PMID: 23766866]
[89]
Sun, X.; Chiu, C.C.; Liebson, E.; Crivello, N.A.; Wang, L.; Claunch, J.; Folstein, M.; Rosenberg, I.; Mwamburi, D.M.; Peter, I.; Qiu, W.Q. Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele. Alzheimer Dis. Assoc. Disord., 2009, 23(3), 238-244.
[http://dx.doi.org/10.1097/WAD.0b013e31819cb3ac] [PMID: 19812466]
[90]
Inoue, M.; Baba, H.; Yamamoto, K.; Shimada, H.; Yamakawa, Y.; Suzuki, T.; Miki, T.; Arai, H. Serum levels of albumin-β-amyloid complex in patients with depression. Am. J. Geriatr. Psychiatry, 2016, 24(9), 764-772.
[http://dx.doi.org/10.1016/j.jagp.2016.05.005] [PMID: 27401050]
[91]
Sun, X.; Steffens, D.C.; Au, R.; Folstein, M.; Summergrad, P.; Yee, J.; Rosenberg, I.; Mwamburi, D.M.; Qiu, W.Q. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch. Gen. Psychiatry, 2008, 65(5), 542-550.
[http://dx.doi.org/10.1001/archpsyc.65.5.542] [PMID: 18458206]
[92]
Moon, Y.S.; Kang, S.H.; No, H.J.; Won, M.H.; Ki, S.B.; Lee, S.K.; Kim, D.H. The correlation of plasma Aβ42 levels, depressive symp-toms, and cognitive function in the Korean elderly. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35(7), 1603-1606.
[http://dx.doi.org/10.1016/j.pnpbp.2011.05.013] [PMID: 21640783]
[93]
Baba, H.; Nakano, Y.; Maeshima, H.; Satomura, E.; Kita, Y.; Suzuki, T.; Arai, H. Metabolism of amyloid-β protein may be affected in depression. J. Clin. Psychiatry, 2012, 73(1), 115-120.
[http://dx.doi.org/10.4088/JCP.10m06766] [PMID: 22152118]
[94]
Namekawa, Y.; Baba, H.; Maeshima, H.; Nakano, Y.; Satomura, E.; Takebayashi, N.; Nomoto, H.; Suzuki, T.; Arai, H. Heterogeneity of elderly depression: increased risk of Alzheimer’s disease and Aβ protein metabolism. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 43, 203-208.
[http://dx.doi.org/10.1016/j.pnpbp.2012.12.016] [PMID: 23276885]
[95]
Blasko, I.; Kemmler, G.; Jungwirth, S.; Wichart, I.; Krampla, W.; Weissgram, S.; Jellinger, K.; Tragl, K.H.; Fischer, P. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am. J. Geriatr. Psychiatry, 2010, 18(11), 973-982.
[http://dx.doi.org/10.1097/JGP.0b013e3181df48be] [PMID: 20808106]
[96]
Metti, A.L.; Cauley, J.A.; Newman, A.B.; Ayonayon, H.N.; Barry, L.C.; Kuller, L.M.; Satterfield, S.; Simonsick, E.M.; Yaffe, K. Plas-ma beta amyloid level and depression in older adults. J. Gerontol. A Biol. Sci. Med. Sci., 2013, 68(1), 74-79.
[http://dx.doi.org/10.1093/gerona/gls093] [PMID: 22499763]
[97]
Direk, N.; Schrijvers, E.M.; de Bruijn, R.F.; Mirza, S.; Hofman, A.; Ikram, M.A.; Tiemeier, H. Plasma amyloid β, depression, and de-mentia in community-dwelling elderly. J. Psychiatr. Res., 2013, 47(4), 479-485.
[http://dx.doi.org/10.1016/j.jpsychires.2012.12.008] [PMID: 23312759]
[98]
Qiu, W.Q.; Zhu, H.; Dean, M.; Liu, Z.; Vu, L.; Fan, G.; Li, H.; Mwamburi, M.; Steffens, D.C.; Au, R. Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer’s disease. Int. J. Geriatr. Psychiatry, 2016, 31(3), 316-322.
[http://dx.doi.org/10.1002/gps.4339] [PMID: 26250797]
[99]
Yamazaki, C.; Tamaoki, T.; Nunomura, A.; Tamai, K.; Yasuda, K.; Motohashi, N. Plasma Amyloid-β and Alzheimer’s Disease-Related Changes in Late-Life Depression. J. Alzheimers Dis., 2017, 58(2), 349-354.
[http://dx.doi.org/10.3233/JAD-170111] [PMID: 28453490]
[100]
Clarke, N.A.; Hartmann, T.; Jones, E.L.; Ballard, C.G.; Francis, P.T. Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aβ 40 and tau in patients with intractable unipolar depression. Int. J. Geriatr. Psychiatry, 2011, 26(12), 1283-1291.
[http://dx.doi.org/10.1002/gps.2678] [PMID: 21308788]
[101]
Kranaster, L.; Aksay, S.S.; Bumb, J.M.; Janke, C.; Alonso, A.; Hoyer, C.; Zerr, I.; Schmitz, M.; Hausner, L.; Frölich, L.; Sartorius, A. Electroconvulsive therapy selectively enhances amyloid β 1-42 in the cerebrospinal fluid of patients with major depression: A prospec-tive pilot study. Eur. Neuropsychopharmacol., 2016, 26(12), 1877-1884.
[http://dx.doi.org/10.1016/j.euroneuro.2016.11.004] [PMID: 27876183]
[102]
Hock, C.; Golombowski, S.; Müller-Spahn, F.; Naser, W.; Beyreuther, K.; Mönning, U.; Schenk, D.; Vigo-Pelfrey, C.; Bush, A.M.; Moir, R.; Tanzi, R.E.; Growdon, J.H.; Nitsch, R.M. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer’s disease and major depression - inverse correlation with dementia severity. Eur. Neurol., 1998, 39(2), 111-118.
[http://dx.doi.org/10.1159/000007917] [PMID: 9520072]
[103]
Reis, T.; Brandão, C.O.; Freire Coutinho, E.S.; Engelhardt, E.; Laks, J. Cerebrospinal fluid biomarkers in Alzheimer’s disease and geri-atric depression: preliminary findings from Brazil. CNS Neurosci. Ther., 2012, 18(7), 524-529.
[http://dx.doi.org/10.1111/j.1755-5949.2012.00311.x] [PMID: 22530600]
[104]
Pomara, N.; Bruno, D.; Sarreal, A.S.; Hernando, R.T.; Nierenberg, J.; Petkova, E.; Sidtis, J.J.; Wisniewski, T.M.; Mehta, P.D.; Pratico, D.; Zetterberg, H.; Blennow, K. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am. J. Psychiatry, 2012, 169(5), 523-530.
[http://dx.doi.org/10.1176/appi.ajp.2011.11081153] [PMID: 22764362]
[105]
Pomara, N.; Bruno, D.; Osorio, R.S.; Reichert, C.; Nierenberg, J.; Sarreal, A.S.; Hernando, R.T.; Marmar, C.R.; Wisniewski, T.; Zetter-berg, H.; Blennow, K. State-dependent alterations in cerebrospinal fluid Aβ42 levels in cognitively intact elderly with late-life major de-pression. Neuroreport, 2016, 27(14), 1068-1071.
[http://dx.doi.org/10.1097/WNR.0000000000000658] [PMID: 27508979]
[106]
Liguori, C.; Pierantozzi, M.; Chiaravalloti, A.; Sancesario, G.M.; Mercuri, N.B.; Franchini, F.; Schillaci, O.; Sancesario, G. When Cog-nitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer’s Disease from Late-Life Depression. Front. Aging Neurosci., 2018, 10, 38.
[http://dx.doi.org/10.3389/fnagi.2018.00038] [PMID: 29527163]
[107]
Wu, K.Y.; Hsiao, I.T.; Chen, C.S.; Chen, C.H.; Hsieh, C.J.; Wai, Y.Y.; Chang, C.J.; Tseng, H.J.; Yen, T.C.; Liu, C.Y.; Lin, K.J. In-creased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(4), 714-722.
[http://dx.doi.org/10.1007/s00259-013-2627-0] [PMID: 24233127]
[108]
Wu, K.Y.; Liu, C.Y.; Chen, C.S.; Chen, C.H.; Hsiao, I.T.; Hsieh, C.J.; Lee, C.P.; Yen, T.C.; Lin, K.J. Beta-amyloid deposition and cog-nitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(6), 1067-1076.
[http://dx.doi.org/10.1007/s00259-015-3291-3] [PMID: 26739329]
[109]
Li, P.; Hsiao, I.T.; Liu, C.Y.; Chen, C.H.; Huang, S.Y.; Yen, T.C.; Wu, K.Y.; Lin, K.J. Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study. EJNMMI Res., 2017, 7(1), 24.
[http://dx.doi.org/10.1186/s13550-017-0273-4] [PMID: 28324341]
[110]
De Winter, F.L.; Emsell, L.; Bouckaert, F.; Claes, L.; Jain, S.; Farrar, G.; Billiet, T.; Evers, S.; Van den Stock, J.; Sienaert, P.; Obbels, J.; Sunaert, S.; Adamczuk, K.; Vandenberghe, R.; Van Laere, K.; Vandenbulcke, M. No association of lower hippocampal volume with alzheimer’s disease pathology in late-life depression. Am. J. Psychiatry, 2017, 174(3), 237-245.
[http://dx.doi.org/10.1176/appi.ajp.2016.16030319] [PMID: 27539488]
[111]
Hye-Geum Kim; E.-J., K.; Eun-Jin, Cheon; Hae-Won, Kim; Bon-Hoon, Koo Association between cerebral amyloid deposition and clin-ical factors including cognitive function in geriatric depression: pilot study using amyloid positron emission tomography. Clin. Psychopharmacol. Neurosci., 2016, 3(4), 378-382.
[112]
Youn, H.; Lee, S.; Han, C.; Kim, S.H.; Jeong, H.G. Association between brain amyloid accumulation and neuropsychological character-istics in elders with depression and mild cognitive impairment. Int. J. Geriatr. Psychiatry, 2019, 34(12), 1907-1915.
[http://dx.doi.org/10.1002/gps.5209] [PMID: 31489705]
[113]
Tateno, A.; Sakayori, T.; Higuchi, M.; Suhara, T.; Ishihara, K.; Kumita, S.; Suzuki, H.; Okubo, Y. Amyloid imaging with [(18)F]florbetapir in geriatric depression: early-onset versus late-onset. Int. J. Geriatr. Psychiatry, 2015, 30(7), 720-728.
[http://dx.doi.org/10.1002/gps.421525335941]
[114]
Yasuno, F.; Kazui, H.; Morita, N.; Kajimoto, K.; Ihara, M.; Taguchi, A.; Yamamoto, A.; Matsuoka, K.; Kosaka, J.; Kudo, T.; Iida, H.; Kishimoto, T.; Nagatsuka, K. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. Int. J. Geriatr. Psychiatry, 2016, 31(8), 920-928.
[http://dx.doi.org/10.1002/gps.4409] [PMID: 26766490]
[115]
Gatchel, J.R.; Rabin, J.S.; Buckley, R.F.; Locascio, J.J.; Quiroz, Y.T.; Yang, H.S.; Vannini, P.; Amariglio, R.E.; Rentz, D.M.; Properzi, M.; Donovan, N.J.; Blacker, D.; Johnson, K.A.; Sperling, R.A.; Marshall, G.A. Longitudinal association of depression symptoms with cognition and cortical amyloid among community-dwelling older adults. JAMA Netw. Open, 2019, 2(8)e198964
[http://dx.doi.org/10.1001/jamanetworkopen.2019.8964] [PMID: 31397865]
[116]
Wu, K.Y.; Hsiao, I.T.; Chen, C.H.; Liu, C.Y.; Hsu, J.L.; Huang, S.Y.; Yen, T.C.; Lin, K.J. Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder. Sci. Rep., 2018, 8(1), 2739.
[http://dx.doi.org/10.1038/s41598-018-21140-3] [PMID: 29426824]
[117]
Babulal, G.M.; Chen, S.; Williams, M.M.; Trani, J.F.; Bakhshi, P.; Chao, G.L.; Stout, S.H.; Fagan, A.M.; Benzinger, T.L.S.; Holtzman, D.M.; Morris, J.C.; Roe, C.M. Depression and alzheimer’s disease biomarkers predict driving decline. J. Alzheimers Dis., 2018, 66(3), 1213-1221.
[http://dx.doi.org/10.3233/JAD-180564] [PMID: 30400098]
[118]
Bibl, M.; Esselmann, H.; Mollenhauer, B.; Weniger, G.; Welge, V.; Liess, M.; Lewczuk, P.; Otto, M.; Schulz, J.B.; Trenkwalder, C.; Kornhuber, J.; Wiltfang, J. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J. Neurochem., 2007, 103(2), 467-474.
[http://dx.doi.org/10.1111/j.1471-4159.2007.04763.x] [PMID: 17662050]
[119]
Hernandez-Guillamon, M.; Delgado, P.; Penalba, A.; Rodriguez-Luna, D.; Molina, C.A.; Rovira, A.; Alvarez-Sabin, J.; Boada, M.; Montaner, J. Plasma β-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener. Dis., 2012, 10(1-4), 320-323.
[http://dx.doi.org/10.1159/000333811] [PMID: 22261638]
[120]
Gurol, M.E.; Irizarry, M.C.; Smith, E.E.; Raju, S.; Diaz-Arrastia, R.; Bottiglieri, T.; Rosand, J.; Growdon, J.H.; Greenberg, S.M. Plas-ma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology, 2006, 66(1), 23-29.
[http://dx.doi.org/10.1212/01.wnl.0000191403.95453.6a] [PMID: 16401840]
[121]
van Dijk, E.J.; Prins, N.D.; Vermeer, S.E.; Hofman, A.; van Duijn, C.M.; Koudstaal, P.J.; Breteler, M.M. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann. Neurol., 2004, 55(4), 570-575.
[http://dx.doi.org/10.1002/ana.20050] [PMID: 15048897]
[122]
Nelson, A.R.; Sweeney, M.D.; Sagare, A.P.; Zlokovic, B.V. Neurovascular dysfunction and neurodegeneration in dementia and Alz-heimer’s disease. Biochim. Biophys. Acta, 2016, 1862(5), 887-900.
[http://dx.doi.org/10.1016/j.bbadis.2015.12.016] [PMID: 26705676]
[123]
Fagan, A.M.; Younkin, L.H.; Morris, J.C.; Fryer, J.D.; Cole, T.G.; Younkin, S.G.; Holtzman, D.M. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann. Neurol., 2000, 48(2), 201-210.
[http://dx.doi.org/10.1002/1531-8249(200008)48:2201:AID-ANA103.0.CO;2-X] [PMID: 10939571]
[124]
Holtzman, D.M.; Bales, K.R.; Wu, S.; Bhat, P.; Parsadanian, M.; Fagan, A.M.; Chang, L.K.; Sun, Y.; Paul, S.M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J. Clin. Invest., 1999, 103(6), R15-R21.
[http://dx.doi.org/10.1172/JCI6179] [PMID: 10079115]
[125]
Leoni, V. The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer’s disease. Clin. Chem. Lab. Med., 2011, 49(3), 375-383.
[http://dx.doi.org/10.1515/CCLM.2011.088] [PMID: 21388338]
[126]
Ye, S.; Huang, Y.; Müllendorff, K.; Dong, L.; Giedt, G.; Meng, E.C.; Cohen, F.E.; Kuntz, I.D.; Weisgraber, K.H.; Mahley, R.W. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. USA, 2005, 102(51), 18700-18705.
[http://dx.doi.org/10.1073/pnas.0508693102] [PMID: 16344478]
[127]
Tedeschini, E.; Levkovitz, Y.; Iovieno, N.; Ameral, V.E.; Nelson, J.C.; Papakostas, G.I. Efficacy of antidepressants for late-life depres-sion: a meta-analysis and meta-regression of placebo-controlled randomized trials. J. Clin. Psychiatry, 2011, 72(12), 1660-1668.
[http://dx.doi.org/10.4088/JCP.10r06531] [PMID: 22244025]
[128]
Cooper, C.; Katona, C.; Lyketsos, K.; Blazer, D.; Brodaty, H.; Rabins, P.; de Mendonça Lima, C.A.; Livingston, G. A systematic review of treatments for refractory depression in older people. Am. J. Psychiatry, 2011, 168(7), 681-688.
[http://dx.doi.org/10.1176/appi.ajp.2011.10081165] [PMID: 21454919]
[129]
Kessing, L.V.; Søndergård, L.; Forman, J.L.; Andersen, P.K. Lithium treatment and risk of dementia. Arch. Gen. Psychiatry, 2008, 65(11), 1331-1335.
[http://dx.doi.org/10.1001/archpsyc.65.11.1331] [PMID: 18981345]
[130]
Inoue, T.; Kitaichi, Y.; Masui, T.; Nakagawa, S.; Boku, S.; Tanaka, T.; Suzuki, K.; Nakato, Y.; Usui, R.; Koyama, T. Pramipexole for stage 2 treatment-resistant major depression: an open study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(8), 1446-1449.
[http://dx.doi.org/10.1016/j.pnpbp.2010.07.035] [PMID: 20708060]
[131]
Corrigan, M.H.; Denahan, A.Q.; Wright, C.E.; Ragual, R.J.; Evans, D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety, 2000, 11(2), 58-65.
[http://dx.doi.org/10.1002/(SICI)1520-6394(2000)11:258:AID-DA23.0.CO;2-H] [PMID: 10812530]
[132]
Lavretsky, H.; Reinlieb, M.; St Cyr, N.; Siddarth, P.; Ercoli, L.M.; Senturk, D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry, 2015, 172(6), 561-569.
[http://dx.doi.org/10.1176/appi.ajp.2014.14070889] [PMID: 25677354]
[133]
Köhler, C.A.; Freitas, T.H.; Maes, M.; de Andrade, N.Q.; Liu, C.S.; Fernandes, B.S.; Stubbs, B.; Solmi, M.; Veronese, N.; Herrmann, N.; Raison, C.L.; Miller, B.J.; Lanctôt, K.L.; Carvalho, A.F. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr. Scand., 2017, 135(5), 373-387.
[http://dx.doi.org/10.1111/acps.12698] [PMID: 28122130]
[134]
Köhler, O.; Benros, M.E.; Nordentoft, M.; Farkouh, M.E.; Iyengar, R.L.; Mors, O.; Krogh, J. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 2014, 71(12), 1381-1391.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.1611] [PMID: 25322082]
[135]
Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry, 2013, 70(1), 31-41.
[http://dx.doi.org/10.1001/2013.jamapsychiatry.4] [PMID: 22945416]
[136]
Jorge, R.E.; Moser, D.J.; Acion, L.; Robinson, R.G. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch. Gen. Psychiatry, 2008, 65(3), 268-276.
[http://dx.doi.org/10.1001/archgenpsychiatry.2007.45] [PMID: 18316673]
[137]
Kerner, N.; Prudic, J. Current electroconvulsive therapy practice and research in the geriatric population. Neuropsychiatry (London), 2014, 4(1), 33-54.
[http://dx.doi.org/10.2217/npy.14.3] [PMID: 24778709]
[138]
Zivin, K.; Kales, H.C. Adherence to depression treatment in older adults: a narrative review. Drugs Aging, 2008, 25(7), 559-571.
[http://dx.doi.org/10.2165/00002512-200825070-00003] [PMID: 18582145]
[139]
Spaans, H.P.; Sienaert, P.; Bouckaert, F.; van den Berg, J.F.; Verwijk, E.; Kho, K.H.; Stek, M.L.; Kok, R.M. Speed of remission in elderly patients with depression: electroconvulsive therapy v. medication. Br. J. Psychiatry, 2015, 206(1), 67-71.
[http://dx.doi.org/10.1192/bjp.bp.114.148213] [PMID: 25323140]
[140]
Bartels, C.; Wagner, M.; Wolfsgruber, S.; Ehrenreich, H.; Schneider, A. Impact of SSRI therapy on risk of conversion from mild cogni-tive impairment to alzheimer’s dementia in individuals with previous depression. Am. J. Psychiatry, 2018, 175(3), 232-241.
[http://dx.doi.org/10.1176/appi.ajp.2017.17040404] [PMID: 29179578]
[141]
Pelton, G.H.; Harper, O.L.; Roose, S.P.; Marder, K.; D’Antonio, K.; Devanand, D.P. Combined treatment with memantine/es-citalopram for older depressed patients with cognitive impairment: a pilot study. Int. J. Geriatr. Psychiatry, 2016, 31(6), 648-655.
[http://dx.doi.org/10.1002/gps.4375] [PMID: 26559790]
[142]
Dale, E.; Pehrson, A.L.; Jeyarajah, T.; Li, Y.; Leiser, S.C.; Smagin, G.; Olsen, C.K.; Sanchez, C. Effects of serotonin in the hippocam-pus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. CNS Spectr., 2016, 21(2), 143-161.
[http://dx.doi.org/10.1017/S1092852915000425] [PMID: 26346726]
[143]
Eliwa, H.; Belzung, C.; Surget, A. Adult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action? Biochem. Pharmacol., 2017, 141, 86-99.
[http://dx.doi.org/10.1016/j.bcp.2017.08.005] [PMID: 28800956]
[144]
Forloni, G.; Balducci, C. Alzheimer’s Disease, Oligomers, and Inflammation. J. Alzheimers Dis., 2018, 62(3), 1261-1276.
[http://dx.doi.org/10.3233/JAD-170819] [PMID: 29562537]
[145]
Tramutola, A.; Lanzillotta, C.; Perluigi, M.; Butterfield, D.A. Oxidative stress, protein modification and Alzheimer disease. Brain Res. Bull., 2017, 133, 88-96.
[http://dx.doi.org/10.1016/j.brainresbull.2016.06.005] [PMID: 27316747]
[146]
Minter, M.R.; Taylor, J.M.; Crack, P.J. The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J. Neurochem., 2016, 136(3), 457-474.
[http://dx.doi.org/10.1111/jnc.13411] [PMID: 26509334]
[147]
Ormonde do Carmo, M.B.; Mendes-Ribeiro, A.C.; Matsuura, C.; Pinto, V.L.; Mury, W.V.; Pinto, N.O.; Moss, M.B.; Ferraz, M.R.; Brunini, T.M. Major depression induces oxidative stress and platelet hyperaggregability. J. Psychiatr. Res., 2015, 61, 19-24.
[http://dx.doi.org/10.1016/j.jpsychires.2014.12.009] [PMID: 25560770]
[148]
Kern, S.; Skoog, I.; Börjesson-Hanson, A.; Blennow, K.; Zetterberg, H.; Ostling, S.; Kern, J.; Gudmundsson, P.; Marlow, T.; Rosen-gren, L.; Waern, M. Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain Behav. Immun., 2014, 41, 55-58.
[http://dx.doi.org/10.1016/j.bbi.2014.05.006] [PMID: 24858658]
[149]
Diniz, B.S.; Sibille, E.; Ding, Y.; Tseng, G.; Aizenstein, H.J.; Lotrich, F.; Becker, J.T.; Lopez, O.L.; Lotze, M.T.; Klunk, W.E.; Reyn-olds, C.F.; Butters, M.A. Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol. Psychiatry, 2015, 20(5), 594-601.
[http://dx.doi.org/10.1038/mp.2014.76] [PMID: 25092249]
[150]
Bacskai, B.J.; Klunk, W.E.; Mathis, C.A.; Hyman, B.T. Imaging amyloid-beta deposits in vivo. J. Cereb. Blood Flow Metab., 2002, 22(9), 1035-1041.
[http://dx.doi.org/10.1097/00004647-200209000-00001] [PMID: 12218409]
[151]
Lesné, S.; Kotilinek, L.; Ashe, K.H. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience, 2008, 151(3), 745-749.
[http://dx.doi.org/10.1016/j.neuroscience.2007.10.054] [PMID: 18155846]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy